Sophiris Bio, Inc.
SPHS
SPHS was delisted on the 11th of March, 2020.
3 hedge funds and large institutions have $71K invested in Sophiris Bio, Inc. in 2020 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 22 closing their positions.
9.28% less ownership
Funds ownership: 9.28% → 0% (-9.3%)
89% less funds holding
Funds holding: 27 → 3 (-24)
94% less capital invested
Capital invested by funds: $1.24M → $71K (-$1.16M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 22
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$461K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$194K |
| 3 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$91K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$90K |
| 5 |
Renaissance Technologies
New York
|
-$84K |
SPHS Hedge Fund Activity: Q1 2020 in Review
3 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in Sophiris Bio, Inc. (SPHS) for Q1 2020, worth a combined $71K — down 94% from $1.24M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of SPHS and 0 opened new positions — a net loss of 22 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $461K sold.
- 3 institutional investors held Sophiris Bio, Inc. (SPHS) as of Q1 2020, down from 27 in Q4 2019.
- Funds reported $71K of Sophiris Bio, Inc. stock for Q1 2020, down 94% quarter-over-quarter.
- 0 funds opened new Sophiris Bio, Inc. positions in Q1 2020 and 22 closed out, a net change of -22 holders.
- The largest Sophiris Bio, Inc. seller in Q1 2020 was Vanguard Group, an estimated $461K sold.
Based on aggregated 13F filings for Q1 2020.